Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-12-20 20:20 7814

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...

2024-12-19 17:02 4238

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...

2024-12-19 01:00 4020

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

* In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous(SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), show...

2024-12-18 21:43 4973

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct ...

2024-12-18 19:34 5992

Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"

HONG KONG, Dec. 18, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International was honored with the highest accolade, the "Outs...

2024-12-18 11:43 3433

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 * The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies,...

2024-12-18 10:59 4620

Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients

SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSI...

2024-12-18 08:00 3051

Xinhua Silk Road: Why is Pien Tze Huang selected as one of China's brands favored by foreigners in 2024

BEIJING, Dec. 17, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang), a time-honored Chinese enterprise mainly engaging in pharmaceutical manufacturing, was selected as one of China's brands favored by foreigners in 2024 at the 2024 China Brand Day gala held i...

2024-12-17 20:40 3334

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Ad...

2024-12-17 11:48 4050

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and over 70% of patients in TANDEM (Fixed Do...

2024-12-16 22:08 3631

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique globalclinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundan...

2024-12-16 10:30 5405

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

SAN FRANCISCO and SUZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-12-16 07:55 4963

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Bushu Pharma's ongoing investments and efforts offer customers state-of-the-art capabilities, increased capacity, and innovative solutions, providing top-tier pharmaceutical manufacturing and supply chain management services. SAN ANTONIO, Dec. 15, 2024 /PRNewswire/ -- Frost & Sullivan researched ...

2024-12-15 13:30 2718

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC...

2024-12-13 10:35 3796

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 3715

Xinhua Silk Road: Pien Tze Huang boosts TCM globalization

BEIJING, Dec. 12, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., aFujian-based traditional Chinese medicine (TCM) company, has been striving to expand its overseas markets, enhancing the influence of TCM in regions such asSoutheast Asia and Europe. Committed to deepening...

2024-12-12 20:43 3152

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...

2024-12-12 18:07 3927

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...

2024-12-12 11:48 3307

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch inBoston ,USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the ...

2024-12-11 14:44 4778

1 ... 53 54 555657 58 59 ... 184